Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network
Crosslin, DR, Owusu‐Obeng, Aniwaa, Wallace, John R. , Almoguera, Berta , Basford, MA, Bielinski, Suzette J. , Carrell, DS, Connolly, John J. , Doheny, KF, Gallego, CJ, Gordon, Allan , Kirby, Jacqueline, Kitchner, Terrie, Manzi, Shannon , Mejia, A R, Pan, Vivian , Perry, Cassandra, Peterson, JF, Prows, CA, Ralston, James D. , Scott, Stuart A. , Scrol, Aaron, Smith, Maureen E. , Stallings, SC, Veldhuizen, Tamra L., Wolf, W.A., Volpi, Simona , Wiley, Kenneth L , Manolio, Teri A. , Böttinger, Erwin P. , Brilliant, MH, Carey, David J. , Chisholm, Rex L. , Chute, CG, Jl, Haines, Håkonarson, Håkon , Harley, JB, Holm, Ingrid A. , Kullo, IJ, Jarvik, GP, Larson, EB, McCarty, Catherine A. , Williams, MS, Denny, Joshua C. , Rasmussen‐Torvik, LJ, Roden, DM, Ritchie, MD, Rasmussen‐Torvik, Laura J. , Jarvik, Gail P. , Peterson, Josh F. , Bush, William S. , Wallace, J, Crawford, Dana C. , Keating, Brendan J. , Perry, CL, Peterson, JF, Stallings, SC, Li, R, Roden, DM, Ritchie, M.D., Holm, Ingrid A , Hakonarson, Hakon , Denny, Joshua C , Jarvik, Gail P , Bielinski, Suzette , Gordon, Adam S , Connolly, John J , Peterson, Josh F , Scott, Stuart A , Rasmussen-Torvik, Laura J

Clinical Pharmacology & Therapeutics | February 9, 2016 | Volume: 100 | Issue: 2 | Pages: 160-169

10.1002/cpt.350 | PMID 26857349 Get It

Genetic variation can affect drug response in multiple ways, although it remains unclear how rare genetic variants affect drug response. The electronic Medical Records and Genomics (eMERGE) Network, collaborating with the Pharmacogenomics Research Network, began eMERGE‐PGx, a targeted sequencing study to assess genetic variation in 82 pharmacogenes critical for implementation of “precision medicine.” The February 2015 eMERGE‐PGx data release includes sequence‐derived data from ∼5,000 clinical subjects. We present the variant frequency spectrum categorized by variant type, ancestry, and predicted function. We found 95.12% of genes have variants with a scaled Combined Annotation‐Dependent Depletion score above 20, and 96.19% of all samples had one or more Clinical Pharmacogenetics Implementation Consortium Level A actionable variants. These data highlight the distribution and scope of genetic variation in relevant pharmacogenes, identifying challenges associated with implementing clinical sequencing for drug treatment at a broader level, underscoring the importance for multifaceted research in the execution of precision medicine.
Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database
Renfro, Lindsay A. , Kerr, David , Gramont, Aimery de , André, Thierry , Guthrie, Katherine A. , Labianca, Roberto , Francini, Guido, Seitz, J. F., O’Callaghan, Chris J. , Twelves, Chris , Haller, Daniel G. , Yothers, Greg , Cheung, Winson Y, de Gramont, Aimery, Saltz, Leonard B. , O'Callaghan, Chris, van Cutsem, Eric, Cheung, Winson Y. , Grothey, Axel , Alberts, Steven R. , Cutsem, Eric Van , Sargent, Daniel J. , André, Thierry , Yothers, Greg

Journal of Clinical Oncology | February 9, 2016 | Volume: 34 | Issue: 11 | Pages: 1182-1189

10.1200/jco.2015.65.1158 | PMID 26858337 Get It

Purpose Factors associated with early mortality after surgery and treatment with adjuvant chemotherapy in colon cancer are poorly understood. We aimed to characterize the determinants of early mortality in a large cohort of colon cancer trial participants. Methods A pooled analysis of 37,568 patients in 25 randomized trials of adjuvant systemic therapy was conducted. Multivariable logistic regression models with several definitions of early mortality (30, 60, and 90 days, and 6 months) were constructed, adjusting for clinically and statistically significant variables. A nomogram for 6-month mortality was developed and validated. Results Median age among patients was 61 years, patient demographics included 54% men and 90% White, 29% and 71% had stage II and III disease, respectively, and 79%, 20%, and 1% had an Eastern Cooperative Oncology Group performance status (PS) of 0, 1, and ≥ 2, respectively. Early mortality was low: 0.3% at 30 days, 0.6% at 60 days, 0.8% at 90 days, and 1.4% at 6 months. Of those patients who died by 6 months post–random assignment, 40% had documented disease recurrence prior to death. Early disease recurrence was associated with a markedly increased risk of death during the first 6 months post-treatment (hazard ratio, 82.6; 95%CI, 66.9 to 102.1). In prognostic analyses, advanced age, male sex, poorer PS, increasing ratio of positive to examined lymph nodes, earlier decade of enrollment, and higher tumor stage and grade predicted a greater likelihood of early mortality, whereas treatment received was not strongly predictive. A multivariable model for 6-month mortality showed strong optimism-adjusted discrimination (concordance index, 0.73) and calibration. Conclusion Early mortality was infrequent but more prevalent in patients with advanced age and a PS of ≥ 2, underscoring the need to carefully consider the risk-to-benefit ratio when making treatment decisions in these subgroups.
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction
Landau, Heather , Comenzo, Raymond L. , Seldin, David C. , Weiss, Brendan M. , Zonder, Jeffrey A. , Merlini, Giampaolo , Schönland, Stefan , Walling, Jackie , Kinney, Gene G. , Koller, Martin, Schenk, Dale B., Guthrie, Spencer , Liedtke, Michaela , Seldin, David, Weiss, Brendan, Zonder, Jeffrey, Guthrie, Spencer D, Gertz, Morie A. , Merlini, Giampaolo , Schönland, Stefan

Journal of Clinical Oncology | February 8, 2016 | Volume: 34 | Issue: 10 | Pages: 1097-1103

10.1200/jco.2015.63.6530 | PMID 26858336 Get It

Purpose Light chain (AL) amyloidosis is caused by the accumulation of misfolded proteins, which induces the dysfunction of vital organs. NEOD001 is a monoclonal antibody targeting these misfolded proteins. We report interim data from a phase I/II dose-escalation/expansion study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction (NCT01707264). Patients and Methods Patients who had completed at least one previous anti–plasma cell-directed therapy, had partial hematologic response or better, and had persistent organ dysfunction received NEOD001 intravenously every 28 days. Dose levels of 0.5, 1, 2, 4, 8, 16, and 24 mg/kg were evaluated (3 + 3 study design). Primary objectives were to determine the maximum tolerated dose and the recommended dose for future studies and to evaluate safety/tolerability. Secondary and exploratory objectives included pharmacokinetics, immunogenicity, and organ responses on the basis of published consensus criteria. Results Twenty-seven patients were enrolled in seven cohorts (dose-escalation component). No drug-related serious adverse events (AEs), discontinuations because of drug-related AEs, dose-limiting toxicities, or antidrug antibodies were reported. The most frequent AEs were fatigue, upper respiratory tract infection, cough, and dyspnea. Recommended dosing was 24 mg/kg. Pharmacokinetics support intravenous dosing every 28 days. Of 14 cardiac-evaluable patients, eight (57%) met the criteria for cardiac response and six (43%) had stable disease. Of 15 renal-evaluable patients, nine (60%) met the criteria for renal response and six (40%) had stable disease. Conclusion Monthly infusions of NEOD001 were safe and well tolerated. Recommended future dosing was 24 mg/kg. Organ response rates compared favorably with those reported previously for chemotherapy. A phase II expansion is ongoing. A global phase III study (NCT02312206) has been initiated. Antibody therapy targeting misfolded proteins is a potential new therapy for the management of AL amyloidosis.
Juvenile idiopathic arthritis and future risk for cardiovascular disease: a multicenter study
Anderson, JH, Anderson, KR, Aulie, HA, Crowson, CS , Mason, T. G., Ardoin, SP, Reed, AM, Flatø, Berit , Anderson, Jason H. , Aulie, Hanne Aaserud , Ardoin, Stacy P. , Anderson, Jason

Scandinavian Journal of Rheumatology | February 8, 2016 | Volume: 45 | Issue: 4 | Pages: 299-303

10.3109/03009742.2015.1126345 | PMID 26854592 Get It

Prevention of Surgical Site Infections in Joint Replacement Surgery
Marculescu, Camelia, Mabry, Tad M. , Berbari, Elie F. , Mabry, Tad

Surgical Infections | February 8, 2016 | Volume: 17 | Issue: 2 | Pages: 152-157

10.1089/sur.2015.258 | PMID 26855288 Get It

Understanding inherited genetic risk of adult glioma – a review
Rice, Terri, Molinaro, Annette M. , Eckel‐Passow, Jeanette E. , Walsh, Kyle M. , Barnholtz‐Sloan, Jill S. , Francis, Stephen , Wiemels, Joseph L. , Jenkins, Robert B. , Wrensch, Margaret , Barnholtz-Sloan, Jill, Francis, Stephen S, Wiemels, Joseph, Wiencke, John K. , Wrensch, Margaret R, Lachance, Daniel Honore , Molinaro, Annette M. , Ostrom, Quinn T. , Barnholtz-Sloan, Jill S , Francis, Stephen S

Neuro-Oncology Practice | February 8, 2016 | Volume: 3 | Issue: 1 | Pages: 10-16

10.1093/nop/npv026 | PMID 26941959 Get It

Abstract During the past six years, researchers have made major progress identifying common inherited genetic variation that increases risk for primary adult glioma. This paper summarizes knowledge about rare familial cancer syndromes that include adult glioma and reviews the available literature on the more recently discovered common inherited variation. Ten independent inherited variants in eight chromosomal regions have been convincingly associated with increased risk for adult glioma. Most of these variants increase relative risk of primary adult glioma by 20% to 40%, but the TP53 variant rs78378222 confers a two-fold relative risk (ie, 200%), and rs557505857 on chromosome 8 confers a six-fold relative risk of IDH-mutated astrocytomas and oligodendroglial tumors (ie, 600%). Even with a six-fold relative risk, the overall risk of developing adult glioma is too low for screening for the high-risk variant on chromosome 8. Future studies will help clarify which inherited adult glioma risk variants are associated with subtypes defined by histology and/or acquired tumor mutations. This review also provides an information sheet for primary adult glioma patients and their families.
Friendly Fire-The Bane of Thermal Ablation
Padmanabhan, Deepak , Asirvatham, Samuel J. , Asirvatham, Samuel J

Pacing and Clinical Electrophysiology | February 8, 2016 | Volume: 39 | Issue: 4 | Pages: 313-315

10.1111/pace.12825 | PMID 26854190 Get It

Novel Percutaneous Epicardial Autonomic Modulation in the Canine for Atrial Fibrillation: Results of an Efficacy and Safety Study
Madhavan, Malini , Venkatachalam, K, Swale, M., Gard, Joseph J., Johnson, Susan B., Suddendorf, Scott H., Mikell, Susan B. , Ladewig, Dorothy J., NOSBUSH, TONI GRABINGER, Danielsen, Andrew J., Knudson, Mark B., Asirvatham, Samuel J. , Knudson, Mark, DeSimone, Christopher V. , Asirvatham, Samuel J

Pacing and Clinical Electrophysiology | February 8, 2016 | Volume: 39 | Issue: 5 | Pages: 407-417

10.1111/pace.12824 | PMID 26854009 Get It

BackgroundEndocardial ablation of atrial ganglionated plexi (GP) has been described for treatment of atrial fibrillation (AF). Our objective in this study was to develop percutaneous epicardial GP ablation in a canine model using novel energy sources and catheters.MethodsPhase 1: The efficacy of several modalities to ablate the GP was tested in an open chest canine model (n = 10). Phase 2: Percutaneous epicardial ablation of GP was done in six dogs using the most efficacious modality identified in phase 1 using two novel catheters.ResultsPhase 1: Direct current (DC) in varying doses (blocking [7–12 μA], electroporation [300–500 μA], ablation [3,000–7,500 μA]), radiofrequency ablation (25–50 W), ultrasound (1.5 MHz), and alcohol (2–5 mL) injection were successful at 0/8, 4/12, 5/7, 3/8, 1/5, and 5/7 GP sites. DC (500–5,000 μA) along with alcohol irrigation was tested in phase 2. Phase 2: Percutaneous epicardial ablation of the right atrium, oblique sinus, vein of Marshall, and transverse sinus GP was successful in 5/6 dogs. One dog died of ventricular fibrillation during DC ablation at 5,000 μA. Programmed stimulation induced AF in six dogs, preablation and no atrial arrhythmia in three, flutter in one, and AF in one postablation. Heart rate, blood pressure, effective atrial refractory period, and local atrial electrogram amplitude did not change significantly postablation. Microscopic examination showed elimination of GP, and minimal injury to atrial myocardium.ConclusionPercutaneous epicardial ablation of GP using DC and novel catheters is safe and feasible and may be used as an adjunct to pulmonary vein isolation in the treatment of AF in order to minimize additional atrial myocardial ablation.
FusX: A Rapid One-Step Transcription Activator-Like Effector Assembly System for Genome Science
Alvin, C. H. , McNulty, Melissa S. , Poshusta, Tanya L., Campbell, Jarryd M. , Martínez‐Gálvez, Gabriel , Argue, David P., Lee, Han , Urban, Mark D. , Bullard, Cassandra E., Blackburn, Patrick R. , Man, Toni Ki Fong, Clark, Karl J. , Ekker, Stephen C. , Ma, Alvin C, Lee, Han B, Ekker, Stephen C , Lee, Han B , Clark, Karl J

Human Gene Therapy | February 8, 2016 | Volume: 27 | Issue: 6 | Pages: 451-463

10.1089/hum.2015.172 | PMID 26854857 Get It

Transcription activator-like effectors (TALEs) are extremely effective, single-molecule DNA-targeting molecular cursors used for locus-specific genome science applications, including high-precision molecular medicine and other genome engineering applications. TALEs are used in genome engineering for locus-specific DNA editing and imaging, as artificial transcriptional activators and repressors, and for targeted epigenetic modification. TALEs as nucleases (TALENs) are effective editing tools and offer high binding specificity and fewer sequence constraints toward the targeted genome than other custom nuclease systems. One bottleneck of broader TALE use is reagent accessibility. For example, one commonly deployed method uses a multitube, 5-day assembly protocol. Here we describe FusX, a streamlined Golden Gate TALE assembly system that (1) is backward compatible with popular TALE backbones, (2) is functionalized as a single-tube 3-day TALE assembly process, (3) requires only commonly used basic molecular biology reagents, and (4) is cost-effective. More than 100 TALEN pairs have been successfully assembled using FusX, and 27 pairs were quantitatively tested in zebrafish, with each showing high somatic and germline activity. Furthermore, this assembly system is flexible and is compatible with standard molecular biology laboratory tools, but can be scaled with automated laboratory support. To demonstrate, we use a highly accessible and commercially available liquid-handling robot to rapidly and accurately assemble TALEs using the FusX TALE toolkit. Together, the FusX system accelerates TALE-based genomic science applications from basic science screening work for functional genomics testing and molecular medicine applications.
Extended ellipse-line-ellipse trajectory for long-object cone-beam imaging with a mounted C-arm system
Yu, Zhicong , Lauritsch, Günter, Dennerlein, Frank, Mao, Yanfei , Hornegger, Joachim, Noo, Frédéric , Mao, Yanfei

Physics in Medicine & Biology | February 8, 2016 | Volume: 61 | Issue: 4 | Pages: 1829-1851

10.1088/0031-9155/61/4/1829 | PMID 26854687 Get It

Abstract Recent reports show that three-dimensional cone-beam (CB) imaging with a floor-mounted (or ceiling-mounted) C-arm system has become a valuable tool in interventional radiology. Currently, a circular short scan is used for data acquisition, which inevitably yields CB artifacts and a short coverage in the direction of the patient table. To overcome these two limitations, a more sophisticated data acquisition geometry is needed. This geometry should be complete in terms of Tuy’s condition and should allow continuous scanning, while being compatible with the mechanical constraints of mounted C-arm systems. Additionally, the geometry should allow accurate image reconstruction from truncated data. One way to ensure such a feature is to adopt a trajectory that provides full R-line coverage within the field-of-view (FOV). An R-line is any segment of line that connects two points on a source trajectory, and the R-line coverage is the set of points that belong to an R-line. In this work, we propose a novel geometry called the extended ellipse-line-ellipse (ELE) for long-object imaging with a mounted C-arm system. This trajectory is built from modules consisting of two elliptical arcs connected by a line. We demonstrate that the extended ELE can be configured in many ways so that full R-line coverage is guaranteed. Both tight and relaxed parametric settings are presented. All results are supported by extensive mathematical proofs provided in appendices. Our findings make the extended ELE trajectory attractive for axially-extended FOV imaging in interventional radiology.